Limits...
Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel.

Wang B, Lv L, Wang Z, Jiang Y, Lv W, Liu X, Wang Z, Zhao Y, Xin H, Xu Q - Sci Rep (2015)

Bottom Line: The in vitro anti-proliferation evaluation showed that the IC50 were 146 ng/ml and 349 ng/ml of Pep-NP-PTX and NP-PTX, respectively.The in vivo fluorescent image results indicated that Pep-NP had higher specificity and efficiency in intracranial tumor accumulation.Pep-NP-PTX could improve the anti-glioma efficacy with a median survival time of 32 days, which was significantly longer than that of PTX-NP (23 days) and Taxol(®) (22 days).

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

ABSTRACT
Glioma presents one of the most malignant brain tumors, and the therapeutic effect is often limited due to the existence of brain tumor barrier. Based on interleukin-13 receptor α2 (IL-13Rα2) over-expression on glioma cell, it was demonstrated to be a potential receptor for glioma targeting. In this study, Pep-1-conjugated PEGylated nanoparticles loaded with paclitaxel (Pep-NP-PTX) were developed as a targeting drug delivery system for glioma treatment. The Pep-NP-PTX presented satisfactory size of 95.78 nm with narrow size distribution. Compared with NP-PTX, Pep-NP-PTX exhibited significantly enhanced cellular uptake in C6 cells (p < 0.001). The in vitro anti-proliferation evaluation showed that the IC50 were 146 ng/ml and 349 ng/ml of Pep-NP-PTX and NP-PTX, respectively. The in vivo fluorescent image results indicated that Pep-NP had higher specificity and efficiency in intracranial tumor accumulation. Following intravenous administration, Pep-NP-PTX could enhance the distribution of PTX in vivo glioma section, 1.98, 1.91 and 1.53-fold over that of NP-PTX group after 0.5, 1 and 4 h, respectively. Pep-NP-PTX could improve the anti-glioma efficacy with a median survival time of 32 days, which was significantly longer than that of PTX-NP (23 days) and Taxol(®) (22 days). In conclusion, Pep-NP-PTX is a potential targeting drug delivery system for glioma treatment.

No MeSH data available.


Related in: MedlinePlus

Cellular uptake of PTX-loaded NP and Pep-NP at 37 °C after incubation for 2 h at the PTX concentrations from 10 μg/mL to 60 μg/mL in C6 cells.Data represented mean ± SD (n = 3). ***p < 0.001 significantly higher than that of Taxol®, ###p < 0.001 significantly higher than that of NP-PTX.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4645113&req=5

f3: Cellular uptake of PTX-loaded NP and Pep-NP at 37 °C after incubation for 2 h at the PTX concentrations from 10 μg/mL to 60 μg/mL in C6 cells.Data represented mean ± SD (n = 3). ***p < 0.001 significantly higher than that of Taxol®, ###p < 0.001 significantly higher than that of NP-PTX.

Mentions: The quantitative cellular uptake of PTX-loaded Pep-NP in C6 cells which was shown concentration-dependent model was presented in Fig. 3. From the results, it could be seen that the cellular uptake of Pep-NP group was 1.55, 1.65, 1.42 and 1.58 folds higher than that of NP group, and 3.39, 3.06, 3.11 and 3.03 folds higher than that of Taxol® group at 37 °C at the PTX concentration of 10, 20, 40 and 60 μg/mL, respectively.


Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel.

Wang B, Lv L, Wang Z, Jiang Y, Lv W, Liu X, Wang Z, Zhao Y, Xin H, Xu Q - Sci Rep (2015)

Cellular uptake of PTX-loaded NP and Pep-NP at 37 °C after incubation for 2 h at the PTX concentrations from 10 μg/mL to 60 μg/mL in C6 cells.Data represented mean ± SD (n = 3). ***p < 0.001 significantly higher than that of Taxol®, ###p < 0.001 significantly higher than that of NP-PTX.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4645113&req=5

f3: Cellular uptake of PTX-loaded NP and Pep-NP at 37 °C after incubation for 2 h at the PTX concentrations from 10 μg/mL to 60 μg/mL in C6 cells.Data represented mean ± SD (n = 3). ***p < 0.001 significantly higher than that of Taxol®, ###p < 0.001 significantly higher than that of NP-PTX.
Mentions: The quantitative cellular uptake of PTX-loaded Pep-NP in C6 cells which was shown concentration-dependent model was presented in Fig. 3. From the results, it could be seen that the cellular uptake of Pep-NP group was 1.55, 1.65, 1.42 and 1.58 folds higher than that of NP group, and 3.39, 3.06, 3.11 and 3.03 folds higher than that of Taxol® group at 37 °C at the PTX concentration of 10, 20, 40 and 60 μg/mL, respectively.

Bottom Line: The in vitro anti-proliferation evaluation showed that the IC50 were 146 ng/ml and 349 ng/ml of Pep-NP-PTX and NP-PTX, respectively.The in vivo fluorescent image results indicated that Pep-NP had higher specificity and efficiency in intracranial tumor accumulation.Pep-NP-PTX could improve the anti-glioma efficacy with a median survival time of 32 days, which was significantly longer than that of PTX-NP (23 days) and Taxol(®) (22 days).

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

ABSTRACT
Glioma presents one of the most malignant brain tumors, and the therapeutic effect is often limited due to the existence of brain tumor barrier. Based on interleukin-13 receptor α2 (IL-13Rα2) over-expression on glioma cell, it was demonstrated to be a potential receptor for glioma targeting. In this study, Pep-1-conjugated PEGylated nanoparticles loaded with paclitaxel (Pep-NP-PTX) were developed as a targeting drug delivery system for glioma treatment. The Pep-NP-PTX presented satisfactory size of 95.78 nm with narrow size distribution. Compared with NP-PTX, Pep-NP-PTX exhibited significantly enhanced cellular uptake in C6 cells (p < 0.001). The in vitro anti-proliferation evaluation showed that the IC50 were 146 ng/ml and 349 ng/ml of Pep-NP-PTX and NP-PTX, respectively. The in vivo fluorescent image results indicated that Pep-NP had higher specificity and efficiency in intracranial tumor accumulation. Following intravenous administration, Pep-NP-PTX could enhance the distribution of PTX in vivo glioma section, 1.98, 1.91 and 1.53-fold over that of NP-PTX group after 0.5, 1 and 4 h, respectively. Pep-NP-PTX could improve the anti-glioma efficacy with a median survival time of 32 days, which was significantly longer than that of PTX-NP (23 days) and Taxol(®) (22 days). In conclusion, Pep-NP-PTX is a potential targeting drug delivery system for glioma treatment.

No MeSH data available.


Related in: MedlinePlus